SGSusan Gruber

Susan Gruber

*This is an algorithmically generated author record based on publicly available information.

Susan Gruber has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transportability to the European Population of Efficacy of Belumosudil as Compared With Physician’s Choice of Best Available Therapy for the Treatment of Chronic Graft Versus Host Disease

    by Daniel Wolff, Carlos Solano, David Michonneau, Francesca Bonifazi, Varun Mehra, Kevin Hall, Aleksandr Lazaryan, Catherine J. Lee, Aaron C. Logan, Mark van der Laan, et al.


  • Open Access

    Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States

    by Kevin Hall, Aleksandr Lazaryan, Mark van der Laan, Catherine Lee, Aaron C. Logan, Susan Gruber, Shaum Kabadi, Irfan Khan, Charlie Nicholls, Lauren Rota, et al.

    Belumosudil was approved by the Food and Drug Administration in the United States for the treatment of relapsed/refractory chronic graft-versus-host disease (cGVHD) based on a randomized phase 2 trial comparing 2 belumosudil doses. The efficacy and safety of belumosudil vs the best available therapy (BAT) has not been studied. Applying rigorous statistical methodology to real-world data, this study estimated the efficacy of belumosudil vs BAT in cGVHD patients whose disease failed to respond to 2 to 5 prior lines of therapy (LOTs). Retrospective data between March 2015 and 2024 were collected across 8 US sites for 196 patients, contributing 113 belumosudil and 245 BAT LOTs. The primary outcome was 6-month overall response rate (ORR), defined as the proportion of complete or partial responses based on 2014 National Institutes of Health consensus criteria, physician assessment, or corticosteroid dose taper of ≥50% without cGVHD progression. Death, relapse, and beginning a new LOT were considered a lack of response. Targeted maximum likelihood estimation (TMLE) was used to estimate the 6-month ORR following belumosudil vs BAT (38.7% vs 26.8%, respectively) or 44.2% improvement with belumosudil (1-sided 95% confidence interval [CI], [4.4 to ∞]; P = .031). TMLE was also used to estimate 1-year failure-free survival when treated with belumosudil (61.2%) or BAT (47.8%), a 13.5% difference (95% CI, 1.5-100; P = .032). Descriptive assessment of safety showed adverse events recorded in 27% of belumosudil and 36% of BAT LOTs. Findings demonstrated that belumosudil improved clinical outcomes compared to BAT in cGVHD patients with 2 to 5 prior LOTs, and safety was consistent with belumosudil’s established profile.


  • Sensitivity Analysis for Unmeasured Confounding in Medical Product Development and Evaluation Using Real World Evidence

    by Yixin Fang, Pallavi Mishra-Kalyani, Xiang Zhang, Susan Gruber, Shu Yang, Peng Ding, Mingyang Shan, Joo-Yeon Lee, Mark van der Laan, Douglas Faries, et al.


  • Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective

    by Jie Chen, Lei Nie, Shiowjen Lee, Haitao Chu, Haijun Tian, Yan Wang, Weili He, Thomas Jemielita, Susan Gruber, Yang Song, et al.

    Developing drugs for rare diseases presents unique challenges from a statistical perspective. These challenges may include slowly progressive diseases with unmet medical needs, poorly understood natural history, small population size, diversified phenotypes and genotypes within a disorder, and lack of appropriate surrogate endpoints to measure clinical benefits. The Real‐World Evidence (RWE) Scientific Working Group of the American Statistical Association Biopharmaceutical Section has assembled a research team to assess the landscape including challenges and possible strategies to address these challenges and the role of real‐world data (RWD) and RWE in rare disease drug development. This paper first reviews the current regulations by regulatory agencies worldwide and then discusses in more detail the challenges from a statistical perspective in the design, conduct, and analysis of rare disease clinical trials. After outlining an overall development pathway for rare disease drugs, corresponding strategies to address the challenges are presented. Other considerations are also discussed for generating relevant evidence for regulatory decision‐making on drugs for rare diseases. The accompanying paper discusses how RWD and RWE can be used to improve the efficiency of rare disease drug development.


  • Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective

    by Jie Chen, Susan Gruber, Hana Lee, Haitao Chu, Shiowjen Lee, Haijun Tian, Yan Wang, Weili He, Thomas Jemielita, Yang Song, et al.

    Real‐world data (RWD) and real‐world evidence (RWE) have been increasingly used in medical product development and regulatory decision‐making, especially for rare diseases. After outlining the challenges and possible strategies to address the challenges in rare disease drug development (see the accompanying paper), the Real‐World Evidence (RWE) Scientific Working Group of the American Statistical Association Biopharmaceutical Section reviews the roles of RWD and RWE in clinical trials for drugs treating rare diseases. This paper summarizes relevant guidance documents and frameworks by selected regulatory agencies and the current practice on the use of RWD and RWE in natural history studies and the design, conduct, and analysis of rare disease clinical trials. A targeted learning roadmap for rare disease trials is described, followed by case studies on the use of RWD and RWE to support a natural history study and marketing applications in various settings.


  • Open Access

    Evaluating and improving real-world evidence with Targeted Learning

    by Susan Gruber, Rachael V. Phillips, Hana Lee, John Concato, Mark van der Laan

    Background: The Targeted Learning roadmap provides a systematic guide for generating and evaluating real-world evidence (RWE). From a regulatory perspective, RWE arises from diverse sources such as randomized controlled trials that make use of real-world data, observational studies, and other study designs. This paper illustrates a principled approach to assessing the validity and interpretability of RWE. Methods: We applied the roadmap to a published observational study of the dose–response association between ritodrine hydrochloride and pulmonary edema among women pregnant with twins in Japan. The goal was to identify barriers to causal effect estimation beyond unmeasured confounding reported by the study's authors, and to explore potential options for overcoming the barriers that robustify results. Results: Following the roadmap raised issues that led us to formulate alternative causal questions that produced more reliable, interpretable RWE. The process revealed a lack of information in the available data to identify a causal dose–response curve. However, under explicit assumptions the effect of treatment with any amount of ritodrine versus none, albeit a less ambitious parameter, can be estimated from data. Conclusions: Before RWE can be used in support of clinical and regulatory decision-making, its quality and reliability must be systematically evaluated. The TL roadmap prescribes how to carry out a thorough, transparent, and realistic assessment of RWE. We recommend this approach be a routine part of any decision-making process.


  • Examples of Applying RWE Causal-Inference Roadmap to Clinical Studies

    by Martin Ho, Susan Gruber, Yixin Fang, Douglas E. Faris, Pallavi Mishra-Kalyani, David Benkeser, Mark van der Laan

    A Real-World Evidence (RWE) scientific working group of the American Statistical Association Biopharmaceutical Section has been reviewing the statistical considerations for generating real-world evidence to support regulatory decision making. Randomized clinical trials have been the gold standard for evaluating the safety and efficacy of medical products. However, in many cases, their costs, duration, limited generalizability, and ethical or technical infeasibility might have motivated some to consider alternatives, such as real-world studies. Yet, the studies conducted in a real-world setting may be considered as a lower level of evidence due to the lack of randomization and the presence of confounding bias. To generate robust real-world evidence (RWE) from analyzing real-world data (RWD), we have proposed an RWE Causal Inference Roadmap with targeted learning (Ho et al. 2021). Three key steps in the roadmap are (1) define a target estimand that aligns with the causal estimand of the study objective; (2) select an efficient estimator for estimating the target estimand and an estimator of its uncertainty; and (3) evaluate the robustness of conclusions to violations of untestable causal assumptions. In this paper, we demonstrate how to apply the roadmap to generate RWE using synthetic data based on a real oncology trial.


  • Targeted Learning: Toward a Future Informed by Real-World Evidence

    by Susan Gruber, Rachael V. Phillips, Hana Lee, Martin Ho, John Concato, Mark J. van der Laan

    The 21st Century Cures Act of 2016 includes a provision for the U.S. Food and Drug Administration (FDA) to evaluate the potential use of real-world evidence (RWE) to support new indications for use for previously approved drugs, and to satisfy post-approval study requirements. Extracting reliable evidence from real-world data (RWD) is often complicated by a lack of treatment randomization, potential intercurrent events, and informative loss to follow-up. Targeted Learning (TL) is a sub-field of statistics that provides a rigorous framework to help address these challenges. The TL Roadmap offers a step-by-step guide to generating valid evidence and assessing its reliability. Following these steps produces an extensive amount of information for assessing whether the study provides reliable scientific evidence, including in support of regulatory decision making. This paper presents two case studies that illustrate the utility of following the roadmap. We used targeted minimum loss-based estimation combined with super learning to estimate causal effects. We also compared these findings with those obtained from an unadjusted analysis, propensity score matching, and inverse probability weighting. Non-parametric sensitivity analyses illuminate how departures from (untestable) causal assumptions affect point estimates and confidence interval bounds that would impact the substantive conclusion drawn from the study. TL's thorough approach to learning from data provides transparency, allowing trust in RWE to be earned whenever it is warranted.


  • Open Access

    Practical considerations for specifying a super learner

    by Rachael V. Phillips, Mark J. van der Laan, Hana Lee, Susan Gruber

    Common tasks encountered in epidemiology, including disease incidence estimation and causal inference, rely on predictive modeling. Constructing a predictive model can be thought of as learning a prediction function, i.e., a function that takes as input covariate data and outputs a predicted value. Many strategies for learning these functions from data are available, from parametric regressions to machine learning algorithms. It can be challenging to choose an approach, as it is impossible to know in advance which one is the most suitable for a particular dataset and prediction task at hand. The super learner (SL) is an algorithm that alleviates concerns over selecting the one "right" strategy while providing the freedom to consider many of them, such as those recommended by collaborators, used in related research, or specified by subject-matter experts. It is an entirely pre-specified and data-adaptive strategy for predictive modeling. To ensure the SL is well-specified for learning the prediction function, the analyst does need to make a few important choices. In this Education Corner article, we provide step-by-step guidelines for making these choices, walking the reader through each of them and providing intuition along the way. In doing so, we aim to empower the analyst to tailor the SL specification to their prediction task, thereby ensuring their SL performs as well as possible. A flowchart provides a concise, easy-to-follow summary of key suggestions and heuristics, based on our accumulated experience, and guided by theory.